To be continued today … Genomic Vision

0


(AOF) – Genomic Vision announced on Friday the issue of the 5th and 6th tranche of bonds convertible into shares with share subscription warrants (OCABSA) for an amount of 2 million euros.

As a reminder, in a press release dated June 15, 2020, the company announced the signing of an issue contract on June 11, 2020 with Winance with a view to setting up a financing by issuance of convertible bonds (the “OC”) into ordinary shares to each of which will be attached a share subscription warrant (the “BSA” and together with the shares to which they are attached the “ABSA” and with the OCs the “OCABSAs”), for a maximum total amount of 12 million euros.

The extraordinary general meeting of shareholders of the company which met on October 30, 2020 approved the implementation of this financing.

© AOF

The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written agreement of OPTION FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustive nature or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.





Source link -92